drugset

drugset / Trial / NCT03443492

SLOG vs mFOLFIRINOX as the First-line Treatment in Locally Advanced Uncresectable or Metastatic Pancreatic Cancer

NCT03443492 ↗

Phase 2 Completed 130 enrolled National Health Research Institutes, Taiwan Chang Gung Memorial Hospital · collab China Medical University Hospital · collab E-DA Hospital · collab Kaohsiung Medical University · collab National Cheng-Kung University Hospital · collab National Taiwan University Hospital · collab Taipei Medical University Shuang Ho Hospital · collab Taipei Veterans General Hospital, Taiwan · collab Tri-Service General Hospital (TSGH) · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

A randomized phase II study to compare the efficacy and safety of SLOG or mFOLFIRINOX as a first-line treatment for patients with locally advanced and metastatic pancreatic cancer.

Timeline

Start: 2018-03-26
Primary completion: 2019-11-30
Completion: 2019-11-30

Publications

Chiang NJ, Tsai KK, Hsiao CF, Yang SH, Hsiao HH, Shen WC, Hsu C, Lin YL, Chen JS, Shan YS, Chen LT. A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma-TCOG T1211 study. Eur J Cancer. 2020 Jan;124:123-130. doi: 10.1016/j.ejca.2019.10.023. Epub 2019 Nov 22.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Gemcitabine	Small molecule	800 mg/m2	—
Subject	Irinotecan	Small molecule	150 mg/m2	—
Subject	Leucovorin	Small molecule	30 mg	Oral
Subject	Leucovorin	Small molecule	400 mg/m2	Oral
Subject	Oxaliplatin	Small molecule	85 mg/m2	Intravenous
Subject	S-1	Small molecule	80 mg	Oral
Subject	S-1	Small molecule	120 mg	Oral
Subject	fluorouracil	Small molecule	2400 mg/m2	Intravenous

Indications

No indication recorded.